Compare · DCOY vs NVO
DCOY vs NVO
Side-by-side comparison of Decoy Therapeutics Inc. (DCOY) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCOY and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $197.31B, about 109112.1x DCOY ($1.8M).
- Over the past year, DCOY is down 95.1% and NVO is down 18.0% - NVO leads by 77.0 points.
- DCOY has been more active in the news (10 items in the past 4 weeks vs 6 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for DCOY).
- Company
- Decoy Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $2.80+5.66%
- $44.57-1.33%
- Market cap
- $1.8M
- $197.31B
- 1M return
- -32.69%
- -6.62%
- 1Y return
- -95.06%
- -18.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 10
- 6
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DCOY
- Director Lieber Jonathan I was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)
- Chief Business Officer Marschel Peter Klaus was granted 3,900 shares (SEC Form 4)
- Chief Executive Officer Pierce Frederick Ii was granted 33,455 shares, increasing direct ownership by 2,409% to 34,844 units (SEC Form 4)
- Chief Financial Officer Rosenblum Mark J was granted 9,682 shares, increasing direct ownership by 576% to 11,363 units (SEC Form 4)
- Chief Scientific Officer Hibner Barbara Louise was granted 4,216 shares (SEC Form 4)
- Director Hanish Arnold C was granted 3,000 shares, increasing direct ownership by 718% to 3,418 units (SEC Form 4)
- Director Lammers Paul was granted 2,000 shares, increasing direct ownership by 200,000% to 2,001 units (SEC Form 4)
- Director Burleson Tess was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)
- Director Mcvicar William K. was granted 3,000 shares, increasing direct ownership by 150,000% to 3,002 units (SEC Form 4)
- Director Gauthier Patricia G. was granted 2,000 shares (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S